Heron Therapeutics, Inc.
HRTX
$1.10
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -260.87% | 74.22% | 183.39% | 134.16% | 80.61% |
| Total Depreciation and Amortization | 5.85% | -4.68% | -20.03% | -18.74% | -20.08% |
| Total Amortization of Deferred Charges | -48.01% | 43.06% | 50.71% | 84.05% | 416.44% |
| Total Other Non-Cash Items | 378.05% | -63.03% | -24.46% | -48.22% | -53.73% |
| Change in Net Operating Assets | -14.43% | -250.41% | -43.31% | -318.32% | -50.13% |
| Cash from Operations | -60.52% | -136.06% | 6.79% | -579.84% | 136.73% |
| Capital Expenditure | 100.00% | 67.35% | -- | -155.20% | 45.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 107.69% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 168.78% | 180.48% | 83.10% | 239.89% | 119.62% |
| Cash from Investing | 198.69% | 258.11% | 77.86% | 229.22% | 117.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5,761.11% | 235.43% | -- | 110.45% | -98.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,906.40% | -38.80% | 481.82% | -- | -6.49% |
| Cash from Financing | 95,350.00% | 58.74% | 481.82% | 112.56% | -99.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 261.01% | -33.38% | 20.59% | 100.99% | -65.63% |